EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Effect of fibrosis regionality on atrial fibrillation recurrence: insights from DECAAF II

Ala Assaf iD, Mario Mekhael iD, Charbel Noujaim iD, Nour Chouman iD, Hadi Younes iD, Han Feng iD, Abdelhadi ElHajjar iD, Botao Shan iD, Peter Kistler iD, Omar Kreidieh iD, Nassir Marrouche iD, Eoin Donnellan iD

Europace · 02.08.2023 · 25 (9)

DOI: 10.1093/europace/euad199 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Europace, online erschienen am 10.07.2023. Verfasst von Ala Assaf und 11 weiteren Autor:innen. Beteiligte Einrichtung: Tulane Research Innovation for Arrhythmia Discovery (TRIAD), Tulane University School of Medicine, 1324 Tulane Avenue, Suite A128, New Orleans, LA 70…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Pulmonary Veins. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Medtronic, GE, Siemens.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The amount of fibrosis in the left atrium (LA) predicts atrial fibrillation (AF) recurrence after catheter ablation (CA). We aim to identify whether regional variations in LA fibrosis affect AF recurrence. Methods and results This post hoc analysis of the DECAAF II trial includes 734 patients with persistent AF undergoing first-time CA who underwent late gadolinium enhancement magnetic resonance imaging (LGE-MRI) within 1 month prior to ablation and were randomized to MRI-guided fibrosis ablation in addition to standard pulmonary vein isolation (PVI) or standard PVI only. The LA wall was divided into seven regions: anterior, posterior, septal, lateral, right pulmonary vein (PV) antrum, left PV antrum, and left atrial appendage (LAA) ostium. Regional fibrosis percentage was defined as a region’s fibrosis prior to ablation divided by total LA fibrosis. Regional surface area percentage was defined as an area’s surface area divided by the total LA wall surface area before ablation. Patients were followed up for a year with single-lead electrocardiogram (ECG) devices. The left PV had the highest regional fibrosis percentage (29.30 ± 14.04%), followed by the lateral wall (23.23 ± 13.56%), and the posterior wall (19.80 ± 10.85%). The regional fibrosis percentage of the LAA was a significant predictor of AF recurrence post-ablation (odds ratio = 1.017, P = 0.021), and this finding was only preserved in patients receiving MRI-guided fibrosis ablation. Regional surface area percentages did not significantly affect the primary outcome.

Conclusion

We have confirmed that atrial cardiomyopathy and remodelling are not a homogenous process, with variations in different regions of the LA. Atrial fibrosis does not uniformly affect the LA, and the left PV antral region has more fibrosis than the rest of the wall. Furthermore, we identified regional fibrosis of the LAA as a significant predictor of AF recurrence post-ablation in patients receiving MRI-guided fibrosis ablation in addition to standard PVI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCatheter AblationPulmonary VeinsHumansContrast MediaGadoliniumHeart AtriaFibrosisRecurrenceTreatment Outcome

Stichwörter der Autor:innen

Atrial fibrillationFibrosisLeft atrial wallRegionalScar

Substanzen

Contrast MediaGadolinium

Autor:innen und Institutionen

  • Tulane Research Innovation for Arrhythmia Discovery (TRIAD), Tulane University School of Medicine, 1324 Tulane Avenue, Suite A128, New Orleans, LA 70112, USA.
  • Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA.
  • Clinical Electrophysiology Research Laboratory, Baker Heart and Diabetes Research Institute, Melbourne, Australia.

ORCID-Profile: Ala Assaf, Mario Mekhael, Charbel Noujaim, Nour Chouman, Hadi Younes, Han Feng, Abdelhadi ElHajjar, Botao Shan, Peter Kistler, Omar Kreidieh, Nassir Marrouche, Eoin Donnellan

Förderung

  • Medtronic
  • GE
  • Siemens
  • Boston Scientific
  • Biosense Webster
  • Abbott

Zitieren

APA

Assaf, A., Mekhael, M., Noujaim, C., Chouman, N., Younes, H., Feng, H., ElHajjar, A., Shan, B., Kistler, P., Kreidieh, O., Marrouche, N., & Donnellan, E. (2023). Effect of fibrosis regionality on atrial fibrillation recurrence: insights from DECAAF II. Europace, 25(9). https://doi.org/10.1093/europace/euad199

Vancouver

Assaf A, Mekhael M, Noujaim C, Chouman N, Younes H, Feng H, et al. Effect of fibrosis regionality on atrial fibrillation recurrence: insights from DECAAF II. Europace. 2023;25(9). doi:10.1093/europace/euad199

BibTeX
@article{Assaf2023,
  author = {Assaf, Ala and Mekhael, Mario and Noujaim, Charbel and Chouman, Nour and Younes, Hadi and Feng, Han and ElHajjar, Abdelhadi and Shan, Botao and Kistler, Peter and Kreidieh, Omar and Marrouche, Nassir and Donnellan, Eoin},
  title = {Effect of fibrosis regionality on atrial fibrillation recurrence: insights from DECAAF II},
  journal = {Europace},
  year = {2023},
  volume = {25},
  number = {9},
  doi = {10.1093/europace/euad199}
}
Kostenlos starten →